BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Torrent Pharmaceuticals Ltd. is set to acquire 100% of Curatio Healthcare PVt. Ltd. for Rs 2000 crore. The consideration includes Rs 115 crore of cash and cash equivalents in the acquired business indicating an enterprise value of Rs 1,885 crore.
Curatio has a strong presence in the cosmetic dermatology segment with a portfolio of over 50 brands, marketed in India. Top 10 brands of Curatio account for ~75% of total revenue.
Curatio’s portfolio consists of leading brands such as Tedibar, Atogla, Spoo, B4 Nappi, and Permite, which are ranked among top five brands in their covered market
With this deal, Torrent Pharma will enter the league of top 10 players in the dermatology segment and will be the leader in the cosmetic dermatology space.
Curatio reported revenues of Rs 224 crore in FY22 and is expected to post Rs 275 crore revenue in FY23, thus valuing the deal at 8.4 times and 6.9 times FY22 and FY23E enterprise value/sales, respectively.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
